Andy Batts
Long only, value, growth, momentum

Auxilium Looks Dirt-Cheap With Xiaflex Set To Drive Top-Line

The stock of Auxilium Pharmaceuticals (NASDAQ:AUXL), a specialty biopharmaceutical company, corrected almost 45% in the last 10 months from its 52-week high at $25.54 in the absence of any meaningful catalysts. Since May the stock gradually started to build a positive momentum again after creating a 52-week low at $13.87. Currently Auxilium is consolidating just below $18, and I feel slowly but steadily the stock is heading towards $25 again. In this investment thesis I will explain why the stock is worth buying at the current level with ~75% upside in the next one year.

Company Overview

Auxilium, together with its subsidiaries, develops and markets specialty pharmaceutical products worldwide. Auxilium's lead two products are Testim and Xiaflex. Testim

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details